HC Wainwright Comments on Journey Medical Q3 Earnings

Key Points

• HC Wainwright forecasts Journey Medical Corporation will report Q3 2025 earnings of ($0.08) per share, maintaining a "Buy" rating with a price target of $13.00.
• The company's latest earnings report showed a loss of ($0.16) per share for the quarter, missing consensus estimates, despite revenue exceeding expectations.
• Recent adjustments from analysts include a boost in price targets and ratings, but Zacks Research downgraded the stock from "hold" to a "strong sell" rating.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Journey Medical in a report issued on Monday, August 25th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical's Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.31 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.15 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.09). Journey Medical had a negative net margin of 15.49% and a negative return on equity of 48.69%. The company had revenue of $15.01 million during the quarter, compared to the consensus estimate of $14.93 million.

Other analysts also recently issued research reports about the stock. Lake Street Capital lifted their price target on shares of Journey Medical from $9.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Wall Street Zen downgraded shares of Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th. Finally, Zacks Research downgraded shares of Journey Medical from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $12.17.

Journey Medical Stock Down 0.8%

NASDAQ DERM traded down $0.06 during mid-day trading on Wednesday, hitting $7.21. The company's stock had a trading volume of 132,090 shares, compared to its average volume of 198,183. The company's 50 day simple moving average is $7.27 and its 200 day simple moving average is $6.70. Journey Medical has a twelve month low of $3.54 and a twelve month high of $8.90. The company has a current ratio of 1.27, a quick ratio of 0.95 and a debt-to-equity ratio of 1.11. The firm has a market capitalization of $175.78 million, a price-to-earnings ratio of -18.97 and a beta of 0.80.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds have recently made changes to their positions in DERM. Tang Capital Management LLC bought a new stake in shares of Journey Medical during the 4th quarter worth $6,747,000. Wasatch Advisors LP raised its stake in Journey Medical by 23.8% in the 2nd quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company's stock valued at $8,272,000 after acquiring an additional 221,456 shares during the period. Geode Capital Management LLC raised its stake in Journey Medical by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company's stock valued at $1,884,000 after acquiring an additional 148,612 shares during the period. Citadel Advisors LLC bought a new stake in Journey Medical in the 4th quarter valued at about $174,000. Finally, Pale Fire Capital SE bought a new stake in Journey Medical in the 1st quarter valued at about $161,000. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.